Sm_nmary This study was conducted to increase the anti-tumour potency and reduce the toxic side-effects of tumour necrosis factor alpha (TNF-a). Natural human TNF-a was chemically conjugated with monomethoxy polyethylene glycol (PEG) using succinimidyl coupling of lysine amino groups of TNF-a. The number-average molecular weight of PEG-modified TNF-a (PEG-TNF-() increased with an increase in the reaction time and the initial molar ratio of PEG relative to TNF-a. The resulting modified TNF-a was separated into fractions of various molecular weights. The specific activity of separated PEG-TNF-xs relative to that of native TNF-a gradually decreased with an increase in the degree of PEG modification, but the plasma half-life was drastically increased with the increase in mokcular weight of modified TNF-a. PEG-TNF-ms, in which 29% and 56% of lysine residues were coupled to PEG, had anti-tumour activity approximately 4 and 100 times greater than unmodified TNF-a in the murine Meth-A fibrosarcoma model. Extensive PEG modification did not increase its in vivo activity. A high dose of unmodified TNF-a induced toxic side-effects, but these were not observed with the modified TNF-zs. Optimal PEG modification of TNF-a markedly increased its bioavailability and may facilitate its potential anti-tumour therapeutic use.
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). TNF-a has potentially synergistic anti-tumour effects, such as direct cytotoxicity against tumour cells, indirect cytotoxicity by activating a host immune anti-tumour response and selective impairment of the microcirculation in the capillaries of the tumour tissue (Nobuhara et al., 1987; Debs et al., 1990) . Thus, TNF-z was expected to be a valuable anti-tumour therapeutic agent. However, TNF-a is rapidly cleared from the blood circulation, and excessively high doses of TNF-x are required to produce significant anti-tumour clinical effects (Moritz et al., 1989; Noguchi et al., 1991) .
TNF-x has been found to have unexpected toxic side-effects, typified by pyrexia, tissue inflammation and injury and a lethal endotoxic shock-like syndrome (Blick et al., 1987; Kimura et al., 1987; Debs et al., 1990) . Nevertheless, high doses of TNF-a cause complete regression of various transplanted solid tumours in mice (Carswell et al., 1975; Manda et al., 1987; Tamura et al., 1989) . This suggests that an increase in the bioavailability of TNF-a may increase its clinical potency, thus facilitating more effective use of TNF-x as an anti-tumour drug.
Clinical applications of proteins such as superoxide dismutase (SOD) and adenosine deaminase (ADA) are limited because of their rapid clearance from the blood as a result of glomerular filtration, proteolysis, hepatic uptake and immunogenicity (Pyatak et al., 1980; Hershfield et al., 1991) .
In recent years, chemical modification of proteins with polyethylene glycol (PEG) and albumin has been found to overcome these drawbacks effectively (Kamisaki et al., 1981; Abuchowski et al., 1984; Poznansky, 1986) . For instance, PEG-modified proteins have been proved to have increased plasma half-lives and stability and reduced immunogenicity in vivo. These effects are attnrbuted to the increased molecular weight and steric hindrance that result from PEG attached to proteins. However, the clinical application of such modified proteins is limited as yet. This is because of the conflicting effects of chemical modification of proteins: the transport from blood to target tissues of modified proteins is limited by their high molecular weight, and receptor binding is sterically inhibited, resulting in loss of bioactivity. Nevertheless, an optimal modification could achieve well-balanced tissue transport, receptor binding and plasma clearance. For the molecular design of modified proteins applicable to clinical use, the discovery of the optimisation of modification conditions, determined by the steric hindrance and molecular weight, should be a primary concern.
In this study, we attempted to optimise modification of TNF-x with PEG to increase further its anti-tumour potency. Synthetic PEG-TNF-a was separated into various molecular weight fractions, that is with various degrees of PEG modification, to study the relationship between steric hindrance, molecular weight and anti-tumour activity. This information will enable us to design modified proteins suitable for therapeutic use.
Materials and methods

Materials
Natural human TNF-x was kindly supplied by Hayashibara Biological Laboratories (Okayama, Japan) . N-succinimidyl succinate monomethoxy polyethylene glycol (SS-PEG; MW = 5000) was obtained from Sigma (St Louis, MO, USA).
Carrier-free ['2"I] (1986) , and were expressed in terms of the Japan reference unit (JRU), defined previously (Yamazaki et al., 1986 ).
Pharmacokinetics of PEG-TNF-x
Native TNF-x and PEG-TNF-ms were labelled with '"I by the lactoperoxidase method (Marchalonis, 1969) , yielding Anti-tunour effects of PEG-TNF-os
The anti-tumour effects of a single i.v. injection of native TNF-41 and PEG-TNF-xs on the Meth-A solid tumour-bearing mice was studied. Native TNF-x slightly inhibited tumour growth (Figure 3) , and the necrotic scores were dose-dependently higher at 24 h after i.v. injection on day 7 (Figure 4) . However, all native TNF-a-treated mice died during the experimental period (Table II) The PEG modification most likely occurred at some of the lysine c-amino residues. The molecular weight and degree of PEG modification were found to be controlled by the amount of the activated PEG relative to TNF-a and the coupling reaction time (Figure 1 ). Most modified proteins in previous studies had an extremely broad polydispersion and did not separate into various M. fractions. It was difficult to determine the relationship between steric hindrance, molecular weight and bioactivity by using these broad size range samples, so the synthetic PEG-TNF-xs were separated into various Mn fractions. The specific activity of PEG-TNF-a relative to that of native TNF-a gradually decreased with an increase in the degree of PEG modification (Table I) . Extensive PEG modification resulted in the complete loss of bioactivity in vitro. By contrast, PEG-modified SOD and ADA maintained relatively high specific activities even at an extensive degree of PEG modification (Pyatak et al., 1980; Hershfield et al., 1991) . These findings may be due to the fact that the substrates of SOD and ADA are very small molecules, so the steric hindrance caused by PEG chains attached to proteins may not affect the enzymic activity. In addition, the active site of the proteins may be small enough to be invulnerable to chemical modification. These findings strongly suggest that PEG chains sterically inhibit TNF-receptor binding and that some lysine amino residues of TNF-a play an important role in bioactivities. These results are partly supported by the fact that Lys-l1 fulfils a structural role (Ostade et al.. 1991) . In addition, chemical modification of IFN-y with PEG inhibited receptor binding (Kita et al., 1990) . To determine the mechanisms of the loss of in vitro TNF-a bioactivity after chemical modification, more detailed studies such as receptor binding assays are necessary. As is well known, lysine modification with PEG is random and difficult to control. Therefore, PEG modification at a site that does not inactivate the protein would be preferred. Recently to overcome effectively this drawback of chemical modification, Goodson and Katre (1990) reported that site-directed PEG modification of interleukin 2 sustained full bioactivity relative to native interleukin 2. This sitedirected PEG modification technique may enable us to prepare PEG-TNF-x in which high specific activity is maintained even at a high molecular weight.
Native TNF-a was rapidly cleared from blood, and the plasma half-life was 3.5 min (Figure 2) . The rapid clearance of native TNF-a in mice as a result of glomerular filtration in the kidney, proteolysis and hepatic uptake was predicted.
Attachment of PEG to TNF-x markedly decreased its plasma clearance. The explanation for the decrease in the plasma clearance of PEG-TNF-x may be the shielding of the proteolytic sites in TNF-(x by PEG chains. PEG-modified proteins have been shown to be more resistant to proteolysis than the corresponding unmodified protein (Lisi et al., 1982) . In addition, the renal clearance of PEG-TNF-( is speculated to be prevented by increasing the molecular weight through covalent attachment of PEG. In general, the clearance by the kidney is slower for a larger protein (Maack et al., 1979) . Thus, the glomerular filtration of PEG-modified IL-2 decreased with an increase in its molecular weight (Knauf et al., 1988 ). An increase in the extent of PEG modification caused a progressive increase in the plasma half-life. Therefore, if the size of the modified protein, which is determined by the steric factors as well as the molecular weight, is the rate-determining step in the in vivo clearance mechanism, the molecular weight of the PEG attached to TNF-x may be also important in influencing the pharmacokinetics of PEG-modified TNFY-.
The systemic administration of TNF-x in high doses often induces toxic side-effects (Blick et al., 1987 , Kimura et al., 1987 . Therefore, cancer therapy with TNF-a has been limited to intratumoral administrations (Pfreundschuh et al., 1989 ). In the Meth-A murine solid tumour model, LPEG-TNF-a and MPEG-TNF-x had a higher anti-tumour activity than native TNF-a (Figures 3 and 4) . In particular MPEG-AL a a -iindwd. dPTGuhdH. TNt F Y Tsu&isami eta A TNF-x was 100-fold more potent than natie TNF-a, and induced complete regreson in two of the sev mice at a dose of only 20 JRU (Tabk I). The remaining five mice had a markedly prolongd survival time. At the dose of 1000 JRU of MPEG-TNF-a, which is five times higher than the dose at which the maximal anti-tumour effect was obsrved, no TNF-a-mediated toxicity was detected (data not shown). MPEG-TNF-x enable us to reduc the therpeutic dose of TNF-a, resuling in d s side-effects. We believe that MPEG-TNF-a is a prosng potential anti-tumour agent in systemic therapy. By contrast, HPEG-TNF-a, which has a higher M. than MPEG-TNF-a, did not show an inased anti-tumour response compared with native TNF-a ( Figures 3 and 4 and Table Ii ). It is of interest to consider the diffence in in vivo activity of PEG-TNF-cs. Tlhis difference may be partly accounted for by plasma learance and tissue tansport. LPEG-TNF-a might be easy to transport to tumour tissue, but was rapidly clared because of its smallr molecular size than MPEG-TNF-a, resulting in a decrease in the bioavailability. On the other hand, it might be harder to transport HPEG-TNF-a to tumour tissue than MPEG-TNF-a because of its larger molecular size. Therefore we believe that MPEG-TNF-a among the versions of PEG-TNF-as prepared is the best miodification produet For PEGmodified TNF-a to become appicble to cinical use, the relationship between tissue transport and plasma clarance should be carefuly considered in order to prepare PEGmodified TNF-z with more potent anti-tumour activity.
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